Estimating the effects of patient-reported outcome (PRO) diarrhea and pain measures on PRO fatigue: Data analysis from a phase II study of abemaciclib monotherapy, a CDK4 and CDK6 inhibitor, in patients with HR+/HER2- breast cancer after chemotherapy for metastatic disease—MONARCH 1.Mark E. Boye, Gregory L. Price, Katherine Houghton et al.|Journal of Clinical Oncology|2017Cited by 3